Hedgehog signaling plays an important role in both embryonic pattern formation and in proliferation, survival and differentiation of adult tissues, including T cells. 1, 2 We report here the presence of rare acquired mutations in genes encoding components of the Hedgehog signaling pathway in T-cell acute lymphoblastic leukemia (T-ALL).
In the four cases in which a detailed analysis was possible, we document the ratio. 2 Finally, Ihh promotes T cell differentiation before pre-TCR signal transduction but acts as negative T cell regulator in later developmental stages. 4 Despite the frequent mutation of the Hedgehog pathway in solid tumors, mutations in hematological malignancies have not been described yet. We recently performed exome sequencing in T-ALL and identified several single nucleotide variants (SNVs) in genes encoding members of the Hedgehog pathway. 6 As these SNVs were also detected in DNA from remission, we initially believed that these SNVs were rare polymorphisms. However, upon more detailed analysis, we confirmed that these SNVs were not present in DNA extracted from non-hematopoietic tissues, indicating that these variants were only present in the leukemia cells and in normal hematopoietic cells.
We identified SNVs in different genes of the Hedgehog pathway in 9 T-ALL samples ( Table 1) . Four of these 9 sequence variations were confirmed to be somatic mutations, based on the analysis of available germline DNA of the same individuals (Figure 1) . Remarkably, these four somatic mutations were still detected in DNA extracted from blood cells at time of remission, while other driver mutations (NOTCH1, etc.) detected in these samples were absent at remission as expected ( Of the five other variations detected in Hedgehog components, two were shown to be present in germline DNA, indicating that these were likely rare polymorphisms and these variations were also predicted not to alter protein structure. The other 3 sequence variations, identified in T-ALL samples for which no germline DNA was available, could still represent true somatic mutations, and predictions indicate a damaging effect for two of these variations ( Table 1) .
Two of the detected acquired mutations were truncating mutations of SMO (R726* and R763*), located in the C-terminus of the protein. This C-terminus contains several arginine clusters that are important in blocking the SMO cell surface expression and inhibit the conformational switch of SMO to its active form. 8 The two other acquired mutations are a GLI1 point mutation (S538F) and a GLI3 point mutation (G727R), which are both located downstream of the zinc finger domain and predicted to be damaging for the protein. Moreover, the GLI3-G727R mutation was previously identified in individuals with postaxial polydactyly (PAP), 9 a disease known to be caused by GLI3 defects, reassuring that the GLI3-G727R mutation identified in T-ALL is also affecting GLI3 function.
To confirm the oncogenic properties of SMO-R763*, we used the HEK293T cell system that was previously reported by Barnes et al. in a study of PTCH1 mutants. 10 We reasoned that if the SMO-R763* mutant identified in our study was an activating mutant, we would be able to increase the proliferation of HEK 293T cells by expressing this mutant, and this effect on proliferation would be insensitive to PTCH1
inhibition. As a control we used the SMO-wild type and a known activating mutant SMO-W539L. 11 To distinguish between the effects caused by the overexpression and by the overactivation of SMO, we co-transfected each SMO construct with a PTCH1-wild type construct, with the aim to test if PTCH1 could still inhibit the SMO mutants.
HEK 293T cells transfected with wild type SMO had a clear proliferation advantage that could be partially inhibited by co-expression of PTCH1 (Figure 2A) . Similarly, expression of the SMO-W539L or SMO R763* resulted in increased proliferation of the 293T cells, but these SMO mutants could not be inhibited by PTCH1 coexpression (Figure 2A ). These data demonstrate that the SMO-R763* mutation is a typical SMO activating mutation that is insensitive to PTCH1 inhibition and is capable of stimulating cell proliferation.
We next evaluated the capacity of these two SMO mutants to activate the Hedgehog of 13 mice expressing the SMO mutants showed enlarged lymph nodes with a major T cell infiltration ( Figure 2B) . Nevertheless, none of these mice developed leukemia implying that activation of the hedgehog pathway is not sufficient to cause leukemia.
Taken together, these data clearly demonstrate that SMO-R763* and SMO-R726* mutants can block the T cell development in vivo in a similar way as the mutant SMO-W539L that activates the Hedgehog pathway.
T-ALL is a genetically complex leukemia where multiple genomic aberrations cooperate to transform normal T-cell precursors to fully malignant thymocytes. Here we provide evidence that also components of the Hedgehog pathway can be mutated in T-ALL. As a direct proof for activation of the Hedgehog pathway in T-ALL, we identified acquired mutations in 4 T-ALL samples (SMO-R726*, SMO-R763*, GLI1-S538F and GLI3-G727R). In two additional T-ALL cases we identified variations in PTCH2 and GLI3 that are predicted to affect these proteins, but for which we do not have evidence that these sequence variations are acquired as no germline DNA was available for these patients.
Remarkably, and in contrast to other somatic mutations detected in the T-ALL samples, the somatic mutations in SMO, GLI1 and GLI3 were still present at high frequency at time of remission. This observation can potentially be explained by the de novo acquisition of these mutations early in life in the hematopoietic compartment.
Similar findings were previously reported for a set of TP53 mutations in ALL, as the same mutations were identified in non-tumor hematopoietic cells in remission. 7 It remains of interest to explore this further in future studies. It is also remarkable that this was observed for all 4 somatic mutations in SMO, GLI1 and GLI3, which seems to indicate that such mutations in the Hedgehog pathway are more deleterious early on than during adult hematopoiesis. This is in agreement with previous work illustrating an important role for Gli3 in the control of T-cell differentiation during fetal development and not during adult development. 12 Taken together, our data indicate that the Hedgehog pathway can be activated in a subset of T-ALL, through mutations in critical proteins of the pathway. These data contrast previous reports that showed that the Hedgehog pathway was dispensable for a NOTCH1 driven T-ALL mouse model. 13 These different conclusions may be explained by the differences between the mouse model and the human disease.
NOTCH1 is a very strong oncogene in mouse models (especially when it is overexpressed), while the human leukemias have lower NOTCH1 activation and still require additional mutations for their further evolution towards an aggressive leukemia. In addition, we have to take into account that we only detected a low 
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